The RCMI Center for Cancer Research established through NIH/NIMHD's RCMI program will continue to be a critical support mechanism in driving Xavier's efforts to enhance and expand its biomedical research capabilities. As stated in Section 1, the primary goal of the RCMI is to enhance faculty and programmatic research competitiveness, especially as related to the areas of cancer, minority health disparities and translational research. The Administrative Core will achieve this goal through the following aims:
Aim 1. To provide effective leadership in governing, monitoring and guiding the key activities of the RCMI program;
Aim 2. To provide user-friendly assistance in developing successful proposals for external support and to patent and license intellectual property;
Aim 3. To engage in strategic planning for ongoing development of the RCMI program and coordinate the effort with the University's strategic planning process.
Aim 4. To promote and facilitate the development of a cohesive group of faculty committed to being actively engaged in health disparities and translational research. The Administrative Core will consist of two Pis: Dr. Gene D'Amour and Dr. Guangdi Wang. Dr. Wang will also serve as the Program Director. In addition, there will be two Associate PDs, a Program Advisor/Consultant, and a Program Manager. The Administrative Core members will meet monthly with the Activity Leaders including the Core Directors and Co-Directors to review progress, identify problems, discuss and implement solutions and improvement plans to ensure that each specific aim is achieved as measured by assessment milestones.
|Komati, Rajesh; Mitchell, Carl A; LeBeaud, Anastasia et al. (2018) Tenacic Acids: A New Class of Tenacious Binders to Metal Oxide Surfaces. Chemistry 24:14824-14829|
|Yao, Xin; Gray, Selena; Pham, Tri et al. (2018) Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin. Biochem Biophys Res Commun 495:1240-1248|
|Toro, Tasha B; Edenfield, Samantha A; Hylton, Brandon J et al. (2018) Chelatable trace zinc causes low, irreproducible KDAC8 activity. Anal Biochem 540-541:9-14|
|Echeverri, Margarita; Anderson, David; Nápoles, Anna María et al. (2018) Cancer Health Literacy and Willingness to Participate in Cancer Research and Donate Bio-Specimens. Int J Environ Res Public Health 15:|
|Schexnayder, Chandler; Broussard, Kiera; Onuaguluchi, Demitrius et al. (2018) Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci 19:|
|Ponnapakkam, Tulasi; Saulsberry, Tyjah; Hill, Tarius et al. (2018) Inhibition of breast tumor growth in mice after treatment with ceramide analog 315. Anticancer Drugs 29:898-903|
|Al-Horani, Rami A; Afosah, Daniel K (2018) Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev 38:1974-2023|
|Mei, Suyu; Flemington, Erik K; Zhang, Kun (2018) Transferring knowledge of bacterial protein interaction networks to predict pathogen targeted human genes and immune signaling pathways: a case study on M. tuberculosis. BMC Genomics 19:505|
|Aqeel, Salem M; Huang, Zhongyuan; Walton, Jonathan et al. (2018) Polyvinylidene Fluoride (PVDF)/Polyacrylonitrile (PAN)/Carbon Nanotube Nanocomposites for Energy Storage and Conversion. Adv Compos Hybrid Mater 1:185-192|
|Zheng, Shilong; Guo, Shanchun; Zhong, Qiu et al. (2018) Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 9:149-154|
Showing the most recent 10 out of 244 publications